drugset / Trial / NCT00311870

Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy

NCT00311870

Phase 4 Completed 52 enrolled Steno Diabetes Center Copenhagen Bayer · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

The aim of the study was to compare the renoprotective effect of a long acting calcium antagonist (nisoldipine) with an angiotensin converting enzyme inhibitor (lisinopril)in type 1 diabetic patients with diabetic kidney disease. In total, 51 patients were randomised to treatment with one of these drugs for 4 years. Changes in kidney function, blood pressure and urinary excretion of albumin were measured every 6 months

Timeline

Start
1993-03
Primary completion
Completion
1999-04

Drugs

EvaluationDrugModalityDoseRoute
Subject LISINOPRIL ANHYDROUS Small molecule 10 mg
Subject LISINOPRIL ANHYDROUS Small molecule 20 mg
Subject nisoldipine Small molecule 20 mg
Subject nisoldipine Small molecule 40 mg